Experts seek remedy for health-care waste Seattle Times, United States - The idea is to tackle the handful of preventable, chronic illnesses such as heart disease and diabetes that account for 75 percent of health-care costs. ...
Brain bleed causes fatal stroke at sadly young age SouthCoastToday.com, MA - Nov 26, 2008 It's a magnetic resonance imaging ?- MRI ? scan with dye injected into the arteries to outline any aneurysm. Most authorities don't recommend screening ...
LegalView Publishes Information on A New Brain Injury TransWorldNews (press release), GA - The drug itself is a type 2 diabetes medication that has been allegedly associated with the development of early onset osteoporosis and heart failure among ...
Your health Chicago Daily Herald, IL - Nov 23, 2008 For the study, 24 participants, ages 55 to 76, underwent MRI scans while conducting Internet searches, US News & World Reports writes. ...
So thankful for Ezriel Durham Herald Sun, NC - Nov 29, 2008 Busby learned of a neurosurgeon in Australia, Jeffrey Rosenfeld, who had developed a new procedure for removing HH tumors, and he sent the MRI on a CD disc ...
Take care this holiday season: Don?t drink and drive Allegan County News, MI - Nov 27, 2008 My Hubby Al, who has end-stage COPD/emphysema and Type II diabetes and congestive heart failure is very thankful for the house. He sees how much easier it ...
Source: Google News
Recent News and Articles on the Keywords: diabetes + 0.39 + web Related to the article below (Last Update: 8/7/2008)
National Diabetes program will be showcased at I-95 Health Fair The Times and Democrat, SC - By T&D StaffThursday, August 07, 2008 SANTEE - A national diabetes educational initiative will be part of an annual health fair sponsored by Congressman Jim ...
American Diabetes Association Collaborates With Healia MarketWatch - The new collaboration gives the ADA's diabetes advocates and health professionals an exclusive opportunity to communicate directly with members of Healia's ...
Preventing the Type 2 diabetes epidemic Globe and Mail, Canada - It's estimated that more than two million Canadians have diabetes, a number that's expected to rise to three million by the end of the decade. ...
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus - Y Miyazaki, L Glass, C Triplitt, E Wajcberg, LJ … - American Journal of Physiology- Endocrinology And Metabolism, 2002 - Am Physiological Soc ... Search for citing articles in: ISI Web of Science (5). ... fat (VF) in patients with
type 2 diabetes mellitus (T2DM ... r = 0.46, P < 0.01), and SSF (r = 0.39, P < 0.05 ...
MRI-MNP technique allows to detect pancreatic inflammation in type 1 diabetes
An obstacle to early detection of type 1 diabetes has been the lack of direct, non-invasive technologies to visualize inflammation in the pancreas, an early manifestation of disease.
Instead, clinicians have had to await overt symptoms before diagnosing an individual, by which time destruction of the insulin-producing beta cells of the pancreas has already progressed significantly.
Recent proof-of-principle experiments by Joslin Diabetes Center and Massachusetts General Hospital ( MGH ) researchers, however, offer hope that physicians may one day be able to identify individuals with preclinical type 1 diabetes, and to assess the effectiveness of therapies much earlier than is now possible. Findings of the study is published in the Journal of Clinical Investigation.
Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks its own insulin-producing beta cells and eventually kills them.
Early in this process, white blood cells called T lymphocytes infiltrate the islets of the pancreas ( an inflammatory condition known as insulitis ), causing the blood vessels to become leaky.
Over time, this infiltration of lymphocytes destroys the beta cells, leading to high blood glucose and full-blown diabetes. Today, the only accurate method for detecting the progression or regression of insulitis is a biopsy of the pancreas, which is almost never performed because it is an invasive and potentially risky procedure.
" The most exciting aspect of this study is that it demonstrates that we can, at least in mice, use a non-invasive imaging method to predict at a very early time whether a drug will stop the progression of diabetes or not. In fact, the drug we used in these proof-of-principle experiments is analogous to one currently being tried in humans with diabetes, and so far showing great promise," said Diane Mathis, who led the study together with Christophe Benoist, also from Joslin, and Ralph Weissleder, of MGH.
In this study, the Joslin and MGH researchers used a new imaging technique to reveal the otherwise undetectable inflammation of pancreatic islets in recently diagnosed diabetic mice.
As T lymphocytes invade the pancreas, blood vessels swell, become more permeable, and leak fluid – as well as small molecules carried in the fluid – into surrounding tissues.
In previous experiments, the researchers demonstrated that this leakage can be detected with the help of magnetic nanoparticles ( MNP ) and magnetic resonance imaging ( MRI ).
After being injected intravenously, these MNPs, which are minute particles of iron oxide, travel through the blood vessels of the body including the pancreas.
If pancreatic vessels have become leaky from inflammation, the magnetic particles spill into nearby tissues, where they are "eaten" by scavenger cells called macrophages. Thus, the MNPs become concentrated at the inflamed site and can be spotted by high-resolution MRI.
In their recent study, the researchers applied the MRI-MNP technique to determine whether they could predict which mice would develop autoimmune diabetes and monitor the effectiveness of immune therapy aimed at reversing diabetes.
The goal of this study was to gather data on mouse models that could guide the safe application of the technique in human patients with, or at risk of, type 1 diabetes.
Results of this study suggest that the MRI-MNP imaging technology may be helpful in identifying people at immediate risk of developing autoimmune diabetes, but most of all for early prediction of response to therapy, which might be very useful for reducing the time and cost of clinical trials.
" Because the results in mice looked so good, and because our MGH colleagues have already successfully used essentially the same drug on many patients with prostate cancer," said Benoist, " we have been able to move relatively quickly into clinical trials." Turvey added: " We hope to know soon whether we can use this drug and imaging technique to monitor pancreas inflammation in humans."
